New Data on QoL With Apalutamide in Prostate Cancer
PUBLISHED: 19 SEPTEMBER 2018
The SPARTAN study has already shown that adding apalutamide (Erleada, Janssen Biotech) to standard treatment with androgen-deprivation therapy (ADT) improves metastasis-free survival (MFS) in men with nonmetastatic castration-resistant prostate cancer (nmCRPC). These data led to US approval of the drug, described as a second-generation ADT, earlier this year. Now new data from the same trial shows that the addition of apalutamide does not reduce health-related quality of life (HRQoL), say researchers.